Skip to main content
. Author manuscript; available in PMC: 2020 Mar 1.
Published in final edited form as: JACC Heart Fail. 2019 Mar;7(3):228–238. doi: 10.1016/j.jchf.2019.01.003

Figure 3 – Multivariate Cox proportional hazard ratios associated with spironolactone for all outcomes, men versus women.

Figure 3 –

Spironolactone was associated with a reduced likelihood of all-cause mortality in women but not men with a significant sex-treatment interaction. There were no other significant associations between spironolactone and primary or clinical outcomes.